Roxadustat

Roxadustat (FG-4592), the N-[(4-hydroxy-1-methyl-7-phenoxyisoquinolin-3-yl)carbonyl]glycine derivative and first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) to receive regulatory approval worldwide, is an orally bioavailable small molecule developed by FibroGen, Inc. for the treatment of anemia associated with chronic kidney disease (CKD) in both dialysis-dependent and non-dialysis-dependent patient populations. The compound acts by competitively inhibiting the three isoforms of prolyl hydroxylase domain enzymes (PHD1, PHD2, PHD3) that, under normoxic conditions, hydroxylate proline residues on the oxygen-dependent degradation domain of hypoxia-inducible factor alpha subunits (HIF-1alpha and HIF-2alpha), thereby targeting them for von Hippel-Lindau (VHL) E3 ubiquitin ligase-mediated proteasomal degradation. By reversibly occupying the 2-oxoglutarate binding pocket of the PHD enzymes, roxadustat stabilizes HIF-alpha, permitting its nuclear translocation, heterodimerization with HIF-beta (ARNT), and transcriptional activation of hypoxia-responsive element (HRE)-containing target genes. The principal therapeutic consequence is a dose-dependent, transient elevation of endogenous erythropoietin (EPO) production that remains within or near the physiological range, in contrast to the supraphysiological EPO concentrations produced by injectable erythropoiesis-stimulating agents (ESAs). In addition to EPO induction, roxadustat suppresses hepatic hepcidin expression, upregulates duodenal ferroportin and divalent metal transporter 1 (DMT1), increases transferrin receptor expression, and thereby improves iron absorption, mobilization, and utilization, an effect of particular clinical relevance in the iron-restricted erythropoiesis commonly observed in CKD patients with chronic inflammation. Roxadustat received its first global approval in China in December 2018 for dialysis-dependent CKD anemia, followed by approvals in Japan (2019, Astellas Pharma, marketed as Evrenzo), the European Union (August 2021, European Commission), South Korea, and Chile. In the United States, the Cardiovascular and Renal Drugs Advisory Committee of the Food and Drug Administration voted against approval in July 2021, citing unresolved cardiovascular safety signals (including increased rates of vascular access thrombosis and deep venous thrombosis in dialysis-dependent populations relative to epoetin alfa) and concerns regarding data integrity in the sponsor’s cardiovascular safety analyses. A large Phase 3 clinical program encompassing the ALPS, ANDES, OLYMPUS, ROCKIES, SIERRAS, HIMALAYAS, and PYRENEES trials demonstrated non-inferiority or superiority to placebo and non-inferiority to epoetin alfa for hemoglobin correction and maintenance across CKD populations, with pooled analyses in incident dialysis patients suggesting a 30 percent reduction in major adverse cardiovascular events (MACE) relative to epoetin alfa. Pharmacokinetics are characterized by rapid oral absorption (Tmax approximately 1 to 2 hours), high plasma protein binding (approximately 99 percent), hepatic metabolism predominantly through CYP2C8 oxidation and UGT1A9 glucuronidation, and an elimination half-life of approximately 12 to 15 hours in CKD patients. Clinically significant drug-drug interactions include increased exposure with CYP2C8 inhibitors (gemfibrozil), reduced absorption with phosphate binders (sevelamer, calcium acetate), and inhibition of BCRP and OATP1B1 transporters leading to elevated statin exposures when co-administered. Beyond anemia, preclinical and early clinical evidence suggests potential renoprotective, anti-inflammatory, and cardioprotective properties mediated through HIF-dependent pathways, including protection against ischemia-reperfusion injury, suppression of NF-kappaB-driven inflammatory cytokines, and modulation of lipid metabolism. This monograph reviews the chemistry, synthesis, and structural pharmacology of roxadustat; the molecular mechanism of HIF-PHD inhibition in biochemical and cellular detail; the comprehensive human pharmacokinetic record; preclinical pharmacology across renal, inflammatory, and metabolic models; the clinical evidence base from the global Phase 3 program; sourcing and quality verification considerations; reconstitution and handling; drug interaction and combination considerations; adverse-event and safety signals including the cardiovascular and thrombotic concerns that limited United States approval; and a comparative assessment of five HIF-PHI class members (daprodustat, vadadustat, molidustat, enarodustat, desidustat) against roxadustat on five competency standards.